Abstract 4021
Background
Whole-exome sequencing of plasma cell-free DNA (WES-cfDNA) is an emerging liquid biopsy approach for identification of somatic mutations and yields high-concordance when compared to WES of the tumours of patients with advanced disease. Here we show that sequential WES-cfDNA provides insight regarding the evolution of metastatic breast cancer and that global mutation profiles relate to clinical response and progression to different lines of treatment.
Methods
A patient with inherited BRCA2 breast cancer was recruited at disease relapse and blood samples were then taken over a 2 year period on treatment until death. Whole-exome sequencing was performed on 12 DNA samples: primary tumor, 2 biopsies at relapse and 8 sequential cfDNA samples. Results were validated by targeted amplicon sequencing and ddPCR. Somatic Single Nucleotide Variants (SNVs) were called with Mutect2. Mutational signatures (MS) and their contributions to each sample were detected using the R package deconstructSigs.
Results
WES profiling showed that MS-3 (associated with germline BRCA2 status) was the predominant signature in the primary tumour, whereas the signature of the two relapse biopsies were MS-3, MS-4 and MS-5, and MS-3, MS-4 and MS-6. The first blood sample taken at relapse with bone disease also had a mixed MS profile. The MS-3 signature was detected in cfDNA with progression to lung and initially resolved in response to carboplatin treatment. MS-3 also predominated in cfDNA on subsequent disease progression and was the dominant MS at the time of death. SNV analysis identified a Tier-1 PIK3CA mutation in the primary and relapse tissue, whereas three other Tier-2 mutations in DNM2, DCC and ATP1A1 were specific to relapse, indicative of cancer evolution. All four variants were detected at high levels by WES-cfDNA. Lastly, an ESR1 emergent mutation was identified by targeted sequencing in cfDNA and predicted failure of letrazole therapy.
Conclusions
Our study demonstrates the capacity of sequential WES-cfDNA to capture the genomic profiles of advanced cancer. The MS in cfDNA can be used track tumour evolution, and give insight into the characteristic of the dominant and lethal clone.
Clinical trial identification
Legal entity responsible for the study
University of Leicester.
Funding
Hope Against Cancer, Cancer Research UK, Leicester ECMC.
Editorial Acknowledgement
Disclosure
A. Thomas: Honoraria: Amgen, Servier, BMS. S. Ahmed: Consulting: Novartis, Eisai, AstraZeneca, MSD, BMS. J.A. Shaw: Scientific advisory board: Qiagen; Board member: International Journal of Experimental Pathology. All other authors have declared no conflicts of interest.
Resources from the same session
4679 - Correlative analyses of serum biomarkers and efficacy outcomes in the randomized phase 2 trial of lenvatinib (LEN), everolimus (EVE), or LEN+EVE in patients with metastatic renal cell carcinoma
Presenter: Chung-Han Lee
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5379 - End-to-end learning to predict survival in patients with gastric cancer using convolutional neural networks
Presenter: Armin Meier
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5394 - Detection of Targetable Kinase Fusions in 7260 patients in an integrated Cancer System
Presenter: Ankur Parikh
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5884 - Clinical and analytical validation of an FDA approved comprehensive genomic profiling (CGP) assay incorporating multiple companion diagnostics for targeted and immunotherapies
Presenter: Yali Li
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5912 - SET overexpression promotes colorectal cancer progression and determines poor outcome in patients with localized disease.
Presenter: Blanca Torrejón
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1168 - The functional MDM4 genetic variant in advanced lung adenocarcinoma patients treated with EGFR-TKIs
Presenter: Nasha Zhang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3071 - PD-L1 expression on pre-treatment circulating tumour cells, but not serum VEGF, is predictive of response to pembrolizumab in melanoma
Presenter: Muhammad Khattak
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4062 - Olaparib plus paclitaxel sensitivity in biomarker subgroups of gastric cancer
Presenter: Yu-Zhen Liu
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4801 - A diagnostic model for hepatitis B virus-related hepatocellular carcinoma in China: a large-scale, multi-center study
Presenter: Tian Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4874 - Dissecting Gastric Cancer biology and how and when to use immunotherapy
Presenter: Meghna Das Thakur
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract